Dr. Laurie Smaldone Alsup is the Chief Scientific Officer and Chief Medical Officer for NDA Group. She brings experience driving programs through all stages of development to commercially successful product approvals. Dr. Alsup has more than 30 years of experience in the pharmaceutical industry helping companies develop accelerated commercialization and market access strategies in the U.S. and global markets. Her expertise is broadly focused across multiple therapeutic areas, including cancer, HIV/AIDS, infectious diseases, rare diseases, and metabolic, neurologic, and immunologic disorders. She spent over 20 years at Bristol Myers Squibb in roles of increasing responsibility in clinical development, regulatory strategy, and corporate risk management. She currently serves on the boards of Blackberry Ltd. and Theravance Biopharma.
Dr. Alsup received her M.D. from the Yale School of Medicine, completed her residency in Internal Medicine at Yale New Haven Hospital and a fellowship in Medical Oncology at Yale.